Table 1.
Completeness of national mortality data (percent), coverage of incidence data (percent) and methods of estimation.
| Country | Mortality |
Incidence |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Coverage (%) | Ill-defined (%)a | Methodb | Exceptionsc | Coverage (%) | Methodd | Exceptionsc | |||
| Albania | 55 | 11/19 | 1 | 2000–2009 ↗ 2020 | Kaposi sarcoma; anus, liver, vulva, vagina, and penile cancers from Croatia and Serbia | 0 | 3B | Estimated from mortality with M:I ratios from cancer registries in Southern Europe modele | |
| Austria | 100 | 4/3 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 100 | 1 | 2003–2012 ↗ 2020 | Non-melanoma skin cancers from Tyrol and Vorarlberg (2010–2012 = 2020) |
| Belarus | 100 | 4/13 | 2A | 2018 = 2020 | 100 | 1 | 2003–2012 ↗ 2020 | Prostate cancer (2010–2012 = 2020) | |
| Belgium | 100 | 6/8 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 100 | 1 | 2004–2013 ↗ 2020 | |
| Bosnia and Herzegovina | 93 | 7/7 | 2A | 2011, 2014, 2016 = 2020 | 40 | 3A | Estimated from mortality (all ages)g with M:I ratios from Republika of Srpska cancer registry (2008–2012) | ||
| Bulgaria | 100 | 3/4 | 1 | 2006–2015 ↗ 2020 | Mesothelioma estimated using survival (source EUROCARE-5) | 100 | 1 | 2004–2013 ↗ 2020 | |
| Croatia | 100 | 1/1 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 100 | 1 | 2003–2012 ↗ 2020 | Non-melanoma skin cancers from Bosnia and Herzegovina, Republika of Srpska and Slovenia cancer registries (2008–2012 = 2020) |
| Cyprush | 74 | 3/4 | 1 | 2007–2016 ↗ 2020 | 70 | 1 | 2003–2012 ↗ 2020 | Thyroid cancer (2010–2012 = 2020) | |
| Czechia | 100 | 2/1 | 1 | 2008–2017 ↗ 2020 | 100 | 1 | 2004–2013 ↗ 2020 | ||
| Denmark | 100 | 8/10 | 1 | 2006–2015 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source NORDCAN) | 100 | 1 | 2007–2016 ↗ 2020 | Anus, vulva, vagina, non-melanoma skin and penile cancers, mesothelioma, Kaposi sarcoma (not available in NORDCAN) and brain and central nervous system tumours from Danish cancer registry |
| Estonia | 100 | 2/2 | 1 | 2009–2018 ↗ 2020 | 100 | 1 | 2003–2012 ↗ 2020 | Prostate cancer (2010–2012 = 2020) | |
| Finland | 100 | 1/1 | 1 | 2008–2017 ↗ 2020 | 100 | 1 | 2007–2016 ↗ 2020 | Anus, vulva, vagina, non-melanoma skin and penile cancers, mesothelioma, Kaposi sarcoma (not available in NORDCAN) and brain and central nervous system tumours from Finnish cancer registry | |
| France | 100 | 10/12 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 18 | 3A | Estimated from mortality with M:I ratios from 15 French cancer registries | Thyroid cancer from 8 French cancer registries (2003–2012 ↗ 2020) Kaposi sarcoma, breast, prostate and childhood cancers from 15 French cancer registries (2008–2012 = 2020) Non-melanoma skin cancers from Haut-Rhin cancer registry (2003–2012 ↗ 2020) |
| Germany | 100 | 4/3 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 73 | 1 | 2003–2012 ↗ 2020 (incidence from 8 German cancer registries) | Kaposi sarcoma and childhood cancers (2008–2012 = 2020) |
| Greece | 100 | 5/8 | 1 | 2007–2016 ↗ 2020 | Kaposi sarcoma; mesothelioma; vulva, vagina and penile cancers (2014–2016 = 2020) | 0 | 3B | Estimated from mortality with M:I ratios from cancer registries in Southern Europe modele | Kaposi sarcoma, non-melanoma and childhood cancers (2018–2012 = 2020) |
| Hungary | 100 | 0/0 | 1 | 2008–2017 ↗ 2020 | 0 | 3B | Estimated from mortality with M:I ratios from national cancer registries in Eastern Europe modeli | Thyroid cancer and Hodgkin lymphoma (2008–2012 = 2020) Childhood cancers from paediatric cancer registry (2008–2012 = 2020) |
|
| Iceland | 100 | 3/1 | 1 | 2009–2018 ↗ 2020 | 100 | 1 | 2007–2016 ↗ 2020 | Anus, vulva, vagina, non-melanoma skin and penile cancers, mesothelioma, Kaposi sarcoma (not available in NORDCAN) and brain and central nervous system tumours from Iceland cancer registry | |
| Ireland | 100 | 0/0 | 1 | 2007–2015 ↗ 2020 | 100 | 1 | 2003–2012 ↗ 2020 | Prostate cancer (2010–2012 = 2020) | |
| Italy | 100 | 2/3 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 50 | 3A | Estimated from mortality with M:I ratios from 33 Italian cancer registries | Breast and thyroid cancers from 13 Italian cancer registries (2003–2012 ↗ 2020) Kaposi sarcoma, prostate and childhood cancers from 38 cancer registries (2008–2012 = 2020) Non-melanoma skin cancers from 5 Italian cancer registries (2003–2012 ↗ 2020) |
| Latvia | 100 | 1/1 | 1 | 2006–2015 ↗ 2020 | 100 | 1 | 2003–2012 ↗ 2020 | ||
| Lithuania | 100 | 3/1 | 1 | 2009–2018 ↗ 2020 | 100 | 1 | 2003–2012 ↗ 2020 | Prostate cancer (2010–2012 = 2020) | |
| Luxembourg | 100 | 3/4 | 1 | 2007–2016 ↗ 2020 | 0 | 3B | Estimated from mortality (2012–2016)j with M:I ratios from cancer registries in Belgium and France | Average number of cases (2007–2016) lower than recorded cases of national pathology-based registerk (2013) completed by recorded incidence cases (source national pathology-based register) | |
| Malta | 100 | 1/1 | 1 | 2007–2016 ↗ 2020 | 100 | 1 | 2004–2013 ↗ 2020 | ||
| Moldova | 83 | 1/0 | 1 | 2009–2018 ↗ 2020 | 0 | 3B | Estimated from mortality with M:I ratios from Ukrainian (2013–2015) cancer registry | ||
| Montenegrol | 94 | 18/17 | 2A | 2013 = 2020 | 0 | 2A | 2013 = 2020 | ||
| Netherlands | 100 | 4/5 | 1 | 2008–2017 ↗ 2020 | 100 | 1 | 2004–2013 ↗ 2020 | Liver and pancreatic cancer cases (2004–2013) completed by cancer deaths (source WHO) | |
| North Macedonia | 100 | 7/7 | 1 | 2006–2013 ↗ 2020 | 0 | 3B | Estimated from mortality with M:I ratios from cancer registries in Southern Europe modele | ||
| Norway | 100 | 6/6 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source NORDCAN) | 100 | 1 | 2007–2016 ↗ 2020 | Anus, vulva, vagina, non-melanoma skin and penile cancers, mesothelioma, Kaposi sarcoma (not available in NORDCAN) and brain and central nervous system tumours from Norwegian Cancer Registry |
| Poland | 100 | 12/10 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 33 | 3A | Estimated from mortality with M:I ratios from 6 Polish cancer registries | Breast, prostate and thyroid cancers from the 6 Polish cancer registries (2003–2012 ↗ 2020) Kaposi sarcoma, non-melanoma skin and childhood cancers from the 6 Polish cancer registries (2008–2012 = 2020) |
| Portugal | 100 | 6/8 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 99 | 3A | Estimated from mortality with M:I ratios from 4 Portuguese local cancer registries (2008–2011) | Liver, pancreatic and lung cancers cases completed by cancer deaths (by registry, year, sex and age) Kaposi sarcoma, non-melanoma skin, breast, prostate, thyroid and childhood cancers from the 4 Portuguese cancer registries (2008–2011 = 2020) |
| Romania | 100 | 1/1 | 1 | 2008–2017 ↗ 2020 | 22 | 3B | Estimated from mortality with M:I ratios from cancer registries in Eastern Europe modeli | Childhood cancers from Cluj and Timisoara cancer registries (2008–2011 = 2020) | |
| Russian Federation | 100 | 7/12 | 1 | 2009–2018 ↗ 2020 | Lip, oral cavity and pharynx, colon, rectum, and anus cancers from St-Petersburg and Arkhangelsk Russian cancer registries | 100 | 1 | 2009-2018m ↗ 2020 | Anus and non-melanoma skin cancers, mesothelioma and Kaposi sarcoma from St-Petersburg and Arkhangelsk Russian cancer registries (2008–2012 = 2020) Oesophageal, gastric, liver, pancreatic and lung cancer cases (2009–2018) completed by cancer deaths (source WHO) |
| Serbian | 95 | 6/5 | 1 | 2008-2017o ↗ 2020 | 57 | 3B | Estimated from mortality with M:I ratios from cancer registries in Eastern Europe modeli | Kaposi sarcoma and childhood cancers estimated from Central Serbia cancer registry (2009–2011 = 2020) | |
| Slovakia | 100 | 2/2 | 1 | 2005–2014 ↗ 2020 | 100 | 2A | 2001–2010 = 2020 | ||
| Slovenia | 100 | 3/2 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 100 | 1 | 2003–2012 ↗ 2020 | |
| Spain | 100 | 2/2 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 27 | 3A | Estimated from mortality with M:I ratios from 14 Spanish cancer registries | Breast, prostate and thyroid cancers from 7 cancer registries (2003–2012 ↗ 2020) Kaposi sarcoma, non-melanoma skin and childhood cancers from 14 cancer registries (2008–2012 = 2020) |
| Sweden | 100 | 3/4 | 1 | 2008–2017 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source NORDCAN) | 100 | 1 | 2007–2016 ↗ 2020 | Anus, vulva, vagina, non-melanoma skin and penile cancers, mesothelioma, Kaposi sarcoma (not available in NORDCAN) and brain and central nervous system tumours from Swedish Cancer Registry. Liver and pancreatic cancer cases completed by cancer deaths (source WHO). |
| Switzerland | 100 | 5/4 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 62 | 3A | Estimated from mortality with M:I ratios from 11 Swiss cancer registries | Breast and thyroid cancers estimated from 8 Swiss cancer registries (2003–2012 ↗ 2020) Kaposi sarcoma and Hodgkin lymphoma; nasopharyngeal, anus, vulva, vagina, penile, testis and childhood from 11 cancer registries (2008–2012 = 2020) Non-melanoma skin cancers from 5 cancer registries (2003–2012 ↗ 2020). |
| Ukraine | 93 | 4/4 | 1 | 2008–2017 ↗ 2020 | Data of gallbladder, testis, kidney, thyroid cancers and Hodgkin lymphoma plus ‘other cancers’ from National Cancer Registry of Ukrainef | 100 | 1 | 2006–2015 ↗ 2020 | |
| United Kingdom | 100 | 1/3 | 1 | 2007–2016 ↗ 2020 | Cervical and corpus uteri cancers estimated using survival (source EUROCARE-5) | 100 | 1 | 2004–2013 ↗ 2020 | Non-melanoma skin cancers estimated from Northern Ireland and Scotland (2004–2013 ↗ 2020) |
National cancer mortality data from 2004 to 2018 were extracted from WHO mortality database, unless otherwise specified. National and local cancer incidence data from 2003 to 2018 were received from national and local population-based cancer registries, unless otherwise specified.
‘↗’ projected to.
‘=’ applied to.
Percentages of ill-defined causes of death, most recent year, male/female.
The method to estimate the national sex- and age-specific mortality rates in 2020 is based on estimated numbers obtained as: 1 - Estimates based on national mortality data, projected rates applied to 2020 population 2A - Estimates based on national mortality data, most recent available rates applied to 2020 population.
For descriptions of methods applied in these cancer sites, please refer to https://gco.iarc.fr/today/data/methods/GLOBOCAN2020_annexes.pdf [Accessed January 2021].
The methods to estimate the national sex- and age-specific incidence rates in 2020 are based on estimated numbers obtained as: 1- Estimates based on national or local (coverage greater than 50%) incidence data, projected rates applied to 2020 population 2A - Estimates based on national incidence data, most recent available rates applied to 2020 population 3A - Estimates based on national mortality estimates and M:I ratios derived from country-specific cancer registry data 3B - Estimates based on national mortality estimates and M:I ratios derived from cancer registry data of neighbouring countries.
Southern Europe model includes Croatia, Cyprus, Italy (33 registries), Malta, Slovenia and Spain (14 registries).
Data source: National Cancer Registry of Ukraine, National Institute of Cancer. Cancer in Ukraine 2013–2014, 2014–2015 and 2015–2016. Kyiv, Ukraine Available at http://www.unci.org.ua/, accessed 31-08-2017.
All age incidence partitioned by age using the age distribution from Republika of Srpska.
Incidence and mortality rates (2007–2016, government-controlled area of Cyprus) were projected to 2020 and applied to 2020 population including both Greek and Turkish parts.
Eastern Europe model includes Bulgaria, Romania (2 registries) and Serbia.
5-year mortality 2012–2016 was used because the number of estimated deaths in 2020 was too small for some sites. The estimated numbers of cases (2012–2016) were then divided by 5.
Data source: Nouveaux cas de cancer 2013. Registre morphologique des tumeurs. Laboratoire national de santé. Grand-Duché de Luxembourg, 2015 Available as http://www.lns.public.lu/publications/brochures/RMT_Nouveaux_cas_de_cancer_2013.pdf [Accessed 5 January 2017].
Mortality and Incidence data source: Malignant neoplasms in Montenegro 2013. Podgorica: Insitute of Public Health of Montenegro, Center for Control and Prevention of Non-communicable Diseases, Registry of Malignant Neoplasms of Montenegro, 2018.
Data source: Russian Federation, Moscow Research Oncological Institute. http://www.oncology.ru [Accessed November 2019].
Projected population 2020 for Serbia (source UN) included Kosovo.
Mortality data from WHO excludes Kosovo.